Kindeva, a global CDMO (Contract Development and Manufacturing Organization) and drug delivery expert, has opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, Loughborough.
The facility represents a significant expansion in Kindeva’s metered-dose inhaler services and will develop and test next-generation propellants (NGP) as the industry prepares to move to more environmentally friendly products.
The 150,000 sq ft site offers a range of services across drug development, from early-stage viability, analytical method development, to commercial analysis.
Commenting on the new site, Milton Boyer, CEO of Kindeva, said: “The opening of our Loughborough Headquarters marks a significant milestone in Kindeva’s growth strategy as we continue to innovate, scale, and expand our global footprint.”
The Loughborough HQ will be responsible for developing and analysing NGPs as the industry faces significant legislation aimed at reducing the environmental impact of the propellants currently used in pressurized metered-dose inhalers (pMDIs).
Boyer continued: “Research estimates that inhalers contribute to 0.03% of total global greenhouse gas emissions, and represent 3% of the U.K. National Health Service (NHS) carbon footprint.
“Investment in our Loughborough site, new technologies and people, will allow Kindeva to become the leading force in the industry for sustainability and assuring supply continuity as the industry transitions to low Global Warming Potential (GWP) propellents.”
